180 related articles for article (PubMed ID: 2146144)
1. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders.
Wehmeier A; Fricke S; Scharf RE; Schneider W
Eur J Haematol; 1990 Oct; 45(4):191-7. PubMed ID: 2146144
[TBL] [Abstract][Full Text] [Related]
2. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171
[TBL] [Abstract][Full Text] [Related]
3. In vivo platelet release in myeloproliferative disorders.
Ireland H; Lane DA; Wolff S; Foadi M
Thromb Haemost; 1982 Aug; 48(1):41-5. PubMed ID: 6215739
[TBL] [Abstract][Full Text] [Related]
4. Platelet alpha-granule release in chronic myeloproliferative disorders with thrombocytosis.
Sacchi S; Curci G; Piccinini L; Messerotti A; Cucci F; Bursi R; Zaniol P; Torelli U
Scand J Clin Lab Invest; 1986 Apr; 46(2):163-6. PubMed ID: 2424075
[TBL] [Abstract][Full Text] [Related]
5. Intraplatelet levels of vWF:Ag and fibrinogen in myeloproliferative disorders.
Meschengieser S; Blanco A; Woods A; Maugeri N; Fernandez J; Dupont J; Lazzari MA
Thromb Res; 1987 Nov; 48(3):311-9. PubMed ID: 3501618
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of beta-thromboglobulin in patients with high platelet count.
Fabris F; Randi ML; Casonato A; Dal Bo Zanon R; Bonvicini P; Girolami A
Acta Haematol; 1984; 71(1):32-8. PubMed ID: 6197855
[TBL] [Abstract][Full Text] [Related]
7. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes.
Villmow T; Kemkes-Matthes B; Matzdorff AC
Thromb Res; 2002 Nov; 108(2-3):139-45. PubMed ID: 12590950
[TBL] [Abstract][Full Text] [Related]
8. Generation of arachidonic acid metabolites from stimulated whole blood in patients with chronic myeloproliferative disorders.
Parise P; Huybrechts E; Grasselli S; Falcinelli F; Nenci GG; Gresele P; Vermylen J
Acta Haematol; 1991; 85(2):88-92. PubMed ID: 1902615
[TBL] [Abstract][Full Text] [Related]
9. Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease.
Wehmeier A; Scharf RE; Fricke S; Schneider W
Haemostasis; 1989; 19(5):251-9. PubMed ID: 2777137
[TBL] [Abstract][Full Text] [Related]
10. Platelet survival, platelet factor-4 and bleeding time in myeloproliferative disorders.
Berild D; Hasselbalch H; Knudsen JB
Scand J Clin Lab Invest; 1987 Sep; 47(5):497-501. PubMed ID: 3477851
[TBL] [Abstract][Full Text] [Related]
11. Influence of thrombopoietin on platelet activation in myeloproliferative disorders.
Usuki K; Iki S; Endo M; Izutsu K; Inoue K; Nishimura T; Urabe A
Br J Haematol; 1997 Jun; 97(3):530-7. PubMed ID: 9207394
[TBL] [Abstract][Full Text] [Related]
12. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A
Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085
[TBL] [Abstract][Full Text] [Related]
13. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
14. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
15. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders.
Gersuk GM; Carmel R; Pattengale PK
Blood; 1989 Nov; 74(7):2330-4. PubMed ID: 2804368
[TBL] [Abstract][Full Text] [Related]
16. Assessment of platelet activation in myeloproliferative disorders with complementary techniques.
Bermejo E; Alberto MF; Meschengieser SS; Lazzari MA
Blood Coagul Fibrinolysis; 2004 Apr; 15(3):235-40. PubMed ID: 15060419
[TBL] [Abstract][Full Text] [Related]
17. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
Wehmeier A; Südhoff T; Meierkord F
Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
[TBL] [Abstract][Full Text] [Related]
18. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.
Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A
Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560
[TBL] [Abstract][Full Text] [Related]
19. Abnormal levels of platelet-specific proteins and mitogenic activity in myeloproliferative disease.
Rueda F; Piñol G; Marti F; Pujol-Moix N
Acta Haematol; 1991; 85(1):12-5. PubMed ID: 1826402
[TBL] [Abstract][Full Text] [Related]
20. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo.
Cadroy Y; Horbett TA; Hanson SR
J Lab Clin Med; 1989 Apr; 113(4):436-48. PubMed ID: 2522978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]